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Abstract
Background: The epidemiology of candidemia varies depending on the geographic region. Little is known about the
epidemiology of candidemia in Latin America.
Methods: We conducted a 24-month laboratory-based survey of candidemia in 20 centers of seven Latin American
countries. Incidence rates were calculated and the epidemiology of candidemia was characterized.
Results: Among 672 episodes of candidemia, 297 (44.2%) occurred in children (23.7% younger than 1 year), 36.2% in adults
between 19 and 60 years old and 19.6% in elderly patients. The overall incidence was 1.18 cases per 1,000 admissions, and
varied across countries, with the highest incidence in Colombia and the lowest in Chile. Candida albicans (37.6%), C.
parapsilosis (26.5%) and C. tropicalis (17.6%) were the leading agents, with great variability in species distribution in the
different countries. Most isolates were highly susceptible to fluconazole, voriconazole, amphotericin B and anidulafungin.
Fluconazole was the most frequent agent used as primary treatment (65.8%), and the overall 30-day survival was 59.3%.
Conclusions: This first large epidemiologic study of candidemia in Latin America showed a high incidence of candidemia,
high percentage of children, typical species distribution, with C. albicans, C. parapsilosis and C. tropicalis accounting for the
majority of episodes, and low resistance rates.
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Introduction
Candidemia is the leading invasive mycosis occurring in
hospitalized patients, with a high burden in tertiary care hospitals
worldwide [1,2]. The epidemiology of candidemia has been
extensively described in the Northern Hemisphere, especially in
The USA, Western Europe and Asia [3–15]. In Latin America,
except from Brazil [16–21] and other few reports [22–24], little is
known about the epidemiology of candidemia [25]. The recog-
nition of differences in incidence, populations at greater risk,
species distribution and antifungal susceptibility patters is impor-
tant in order to establish appropriate measures of infection control
and for the management of this disease, including prophylaxis and
empiric antifungal therapy.
In a nationwide prospective multicenter study conducted in
Brazil, a high burden of candidemia was reported, with 2.49 cases
per 1,000 admissions (3–10 times higher than that reported in the
Northern Hemisphere) with a ,50% crude mortality rate [19]. In
addition, epidemiologic studies in Brazil suggested that Candida
parapsilosis and Candida tropicalis were the most frequent non-albicans
species, and the proportion of cases due to Candida glabrata and
Candida krusei was low [25].
The Latin America Invasive Mycosis Network is a group of
investigators interested in invasive mycoses who met first in 2005
to identify priorities in research and educational activities in the
region. In this paper we report the first multicenter prospective
epidemiologic study to investigate the epidemiology of candidemia
in different Latin American countries.
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Patients and Methods
This is a prospective laboratory-based surveillance study
conducted between November 2008 and October 2010 (24
months) in 21 tertiary care hospitals in seven Latin American
countries (total 7,445 beds). They were all general hospitals with
public (n = 12), private (n = 3) or public and private (n = 6) beds.
Sixteen hospitals were for adults and children, one was for adults
only and four were for children. All hospitals had intensive care
units (ICU, 723 beds), internal medicine and surgery; 18 centers
had hematology ward, 10 had solid organ transplantation and 8
had hematopoietic cell transplantation wards. The protocol was
approved by ethics committees of each hospital and country
without the need of written consent, because of the observational
nature of the study: Comite de Etica em Pesquisa da Unifesp/
EPM, Comiteˆ de E´tica em Pesquisas em Seres Humanos do
Hospital de Clı´nicas da Universidade Federal do Parana, Comite
de Etica em Pesquisa do Hospital Pequeno Principe, Comite de
Etica em Pesquisa do Hospital Universita´rio Clementino Fraga
Filho (Brazil); Comite´ de E´tica Cientı´fico Pedia´trico Servicio de
Salud Metropolitano Oriente, Comite´ de E´tica Cientı´fico Clinica
Alemana, Comite´ de E´tica Cientı´fico Facultad de Medicina,
Universidad de Chile (Chile); Comite de Etica del Hospital de
Clinicas Jose de San Martin, Comite de Bioetica, Hospital General
de Agudos Juan A. Fernandez, Comite de Etica e Invedstigacio´n,
Hospital Pedro de Elizalde (Argentina); Hospital Vozandes Quito
Bioethics Committee (Ecuador); Comite´ de Investigaciones y E´tica
Institucional (CIEI) de la Facultad De Medicina de la Pontificia
Universidad Javeriana y del Hospital Universitario De San
Ignacio, Comite de Investigacion, Fundacion Vele del Lili, Comite´
Independente de E´tica en Investigacio´n, Hospital Militar Central,
Comite´ E´tico Cientı´fico de la Empresa Social del Estado Hospital
Universitario de la Samaritana (Colombia), Comite de Etica
Centro Medico de Caracas, Comite de Etica Instituto Medico la
Floresta (Venezuela), Comite Etica de los Postgrados de Medicina
UNAH (Honduras).
Participating institutions carried out laboratory-based sentinel
surveillance for candidemia. All hospitals had automated blood
culture systems (either Bactec or BacT-ALERT), and an
investigator designated to visit the microbiology laboratory on a
daily basis in order to capture all episodes of candidemia, and
trained to prospectively fill a comprehensive case report form once
an episode was diagnosed. The case report form contained
detailed information about demographics, underlying conditions,
coexisting exposures, receipt of antifungal agents and the outcome.
All clinical information was sent using a web-based system (SPSS,
Inc.). Audits and query generation were carried out periodically.
All adult and pediatric patients with candidemia were eligible
for inclusion in the study, and were followed for 30 days. One
episode of candidemia was defined by the isolation of Candida
species from one or more blood cultures in a patient with clinical
signs of infection. If more than one blood culture was positive, a
new episode was defined if more than 30 days had elapsed since
the first positive blood culture (incident candidemia). Break-
through candidemia was defined when the patient was receiving a
systemic antifungal agent for .3 days once candidemia was
diagnosed. Neonates were defined as patients with age #28 days,
infants as children aged .28 days to 1 year, older children as
patients 1–18 years old, adults as patients 19–60 years old, and
elderly as patients .60 years.
All isolates were identified at species level in the local
laboratory, but were also sent to the Special Mycology Laboratory
(Universidade Federal de Sa˜o Paulo) for confirmation of species, as
well as antifungal susceptibility tests. Isolates were identified
according to their microscopic morphology on cornmeal Tween
80 agar, complemented by biochemical tests using the ID 32C
system (BioMe´rieux AS, Marcy l Etoile, France). Sequencing of
the ITS region of ribosomal DNA was used to identify species
other than C. albicans, C. parapsilosis, C. tropicalis, C. glabrata and C.
krusei. Antifungal susceptibility tests were performed using a broth
microdilution assay following the methods recommended by the
Clinical and Laboratory Standards Institute (CLSI) [26]. The
following antifungal drugs were tested: fluconazole (Pfizer Incor-
porated, New York, NY, USA), amphotericin B (Sigma Chemical
Corporation, St Louis, MO, USA), voriconazole and anidulafun-
gin (Pfizer Incorporated, New York, NY, USA). The assays were
incubated at 35uC for 24 h. The minimum inhibitory concentra-
tion (MIC) breakpoints for fluconazole were: for Candida albicans, C.
parapsilosis and C. tropicalis isolates with MIC #2 mg/ml were
considered susceptible, those with MIC 4 mg/ml were considered
susceptible dose-dependent (SDD), and those with MIC$8 mg/ml
were considered resistant; for C. glabrata isolates with MIC
#32 mg/ml were considered SDD, and MIC $64 mg/ml were
considered resistant. All C. krusei isolates were considered resistant
regardless of the MIC value. For voriconazole, isolates with MIC
#2 mg/ml were considered susceptible, those with MIC 4 mg/ml
were considered susceptible dose-dependent (SDD), and those
with MIC$8 mg/ml were considered resistant. For anidulafungin,
isolates of C. albicans, C. tropicalis and C. krusei with MIC #0.25 mg/
ml were considered susceptible, those with MIC 0.5 mg/ml were
intermediate, and isolates with MIC $1 mg/ml were considered
resistant. For C. parapsilosis isolates with MIC #2 mg/ml were
susceptible, 4 mg/ml were intermediate, and $8 mg/ml were
resistant. For C. glabrata the values were as follows: #0.12 mg/ml
susceptible, 0.25 mg/ml intermediate, and $0.5 mg/ml resistant.
For amphotericin B, MICs #1 mg/ml were considered susceptible
and those $2 mg/ml were considered resistant [27].
Incidence density of candidemia was calculated using the
number of episodes of candidemia as numerators, and admissions
and patients-day as denominators. Incidence rates were calculated
for each hospital, each country and overall. Dichotomous variables
were compared using Fisher or Chi-square test, as appropriate,
and continuous variables were compared using the Wilcoxon test.
All statistical analyses were performed in the SPSS software
(version 15, SPSS, Inc.). P values ,0.05 were considered
statistically significant.
Results
During the study period 672 episodes of candidemia were
reported. The median age was 26 years (0–98), and 58.9% were
males. Two hundred and ninety seven episodes (44.2%) occurred
in children (23.7% younger than 1 year, including 89 neonates,
and 20.5% between 1 and 18 years), 36.2% in adults between 19
and 60 years old and 19.6% in elderly patients. Excluding the four
children hospitals the proportion of children in the cohort was still
high (31.2%). The overall incidence was 1.18 cases per 1,000
admissions and 0.23 cases per 1,000 patients-day. As shown in
Table 1, the incidence differed across countries, with the highest
incidence in Argentina (1.95 cases per 1,000 admissions and 0.24
cases per 1,000 patients-day) and the lowest in Chile (0.33 per
1,000 admissions and 0.09 per 1,000 patients-day). There was also
a great variability in the incidence among the centers; the highest
incidence was in an Argentinian hospital with 2.98 cases per 1,000
admissions, and the lowest in a Chilean center (0.21 per 1,000
admissions).
As shown in Table 2, C. albicans was the leading agent (37.6%),
followed by C. parapsilosis (26.5%), C. tropicalis (17.6%), C.
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guilliermondii (6.5%), C. glabrata (6.3%), and C. krusei (2.7%). There
was a great variability in species distribution in the different
countries. Ecuador had the highest proportion of episodes due to
C. albicans (52.2%) and Honduras and Venezuela the lowest
(27.4% and 26.8%, respectively). While C. parapsilosis was highly
prevalent in most countries, it was less frequent in Honduras
(14.1%). By contrast, C. guilliermondii was very common in this
country (20.7%). The highest proportion of episodes caused by C.
glabrata was observed in Brazil (10%) and the lowest was seen in
Venezuela (1 episode, 2.4%).
Overall, cancer was the most frequent underlying condition
(22.5%), and 43.8% of episodes occurred in the context of recent
surgery (within 3 months of the incident candidemia). The median
APACHE II score was 18 (data available in 258 episodes) and
44.6% were in an ICU at the time of the incident candidemia. The
median duration of hospitalization before candidemia was 15 days
(0–176).
As shown in Table 3, characteristics of the episodes of
candidemia differed according to the age strata. For example,
ICU admission was more frequent in neonates, elderly patients
and infants, and less frequent in children (p,0.001); hematologic
malignancies were more prevalent in children while solid tumors
were more frequent in elderly (p,0.001). Co-morbidities like
cardiac, neurologic, lung, liver disease, chronic renal failure and
diabetes were more frequent in elderly patients. By contrast, the
proportion of patients undergoing abdominal surgery was very
similar across age strata.
Species distribution was also different (Table 4). For example,
the proportion of candidemia due to C. glabrata was significantly
higher in elderly patients (15.1% vs. 3.4% in neonates, 1.4% in
infants, 3.6% in children and 4.5% in adults, p,0.001). No other
variable besides age was associated with C. glabrata candidemia,
including prior fluconazole use (3.5% with vs. 6.6% without prior
fluconazole exposure, p = 0.20). For C. guilliermondii, the rates in
children were significantly higher (11.6%) than in other age strata,
whereas C. tropicalis was more frequent in adults. By contrast, there
was no association between age and C. parapsilosis candidemia,
with high rates in all age strata.
Information on antifungal treatment was available in all but 12
episodes (Table 4). Antifungal treatment was given in 85.4% of
episodes, at a median of two days from the date of the incident
candidemia (0–26). In 61 of the 86 (70.9%) episodes of candidemia
in which no antifungal treatment was given, death occurred within
five days from the date of the incident candidemia. Fluconazole
was the most frequent agent used as primary treatment (65.8%),
followed by deoxycholate amphotericin B (24.2%) and an
echinocandin (6.9%). There was an inverse relationship between
age strata and receipt of deoxycholate amphotericin B as primary
therapy for candidemia: 54.9% in neonates, 32.8% in infants, 32%
in older children, 14.1% in adults and 10.3% only in elderly
patients (p,0.001).
The 30-day survival (data available in 583 episodes) was 59.3%
(Table 4). Elderly patients had the lowest 30-day survival rate
(37.7%), followed by neonates (59.7%), adults (61.9%), infants
Table 1. Incidence of candidemia in 20 hospitals of 7 Latin American Countries.
Country Incidence per 1,000 admissions (range) Incidence per 1,000 patients.day (range)
Argentina 1.95 (1.26–2.98) 0.24 (0.13–0.39)
Brazil 1.38 (0.55–2.11) 0.26 (0.14–0.30)
Chile 0.33 (0.21–0.47) 0.09 (0.06–0.16)
Colombia 1.96* 0.16 (0.12–0.24)
Ecuador 0.90 (0.30–1.10) 0.16 (0.10–0.17)
Honduras 0.90 (0.88–0.98) 0.25 (0.24–0.30)
Venezuela 1.72 (1.04–2.90) NA
Overall 1.18 0.23
NA=not available.
*information on number of admission was available in only one hospital.
doi:10.1371/journal.pone.0059373.t001
Table 2. Species distribution of 672 episodes of candidemia.
Argentina Brazil Chile Colombia Ecuador Honduras Venezuela Overall
C. albicans 48 (42.5) 77 (40.5) 16 (42.1) 40 (36.7) 24 (52.2) 37 (27.4) 11 (26.8) 253 (37.6)
C. parapsilosis 27 (23.9) 49 (25.8) 11 (28.9) 42 (38.5) 14 (30.4) 19 (14.1) 16 (39.0) 178 (26.5)
C. tropicalis 19 (16.8) 25 (13.2) 4 (10.5) 19 (17.4) 5 (10.9) 36 (26.7) 10 (24.4) 118 (17.6)
C. guilliermondii 7 (6.2) 3 (1.6) 1 (2.6) 2 (1.8) 1 (2.2) 28 (20.7) 2 (4.9) 44 (6.5)
C. glabrata 7 (6.2) 19 (10.0) 3 (7.9) 5 (4.6) 2 (4.3) 5 (3.7) 1 (2.4) 42 (6.3)
C. krusei 2 (1.8) 9 (4.7) 3 (7.9) – – 4 (3.0) – 18 (2.7)
Other* 3 8 – 1 – 6 1 19 (2.8)
Total 113 190 38 109 46 135 41 672
*Other species – Argentina: C. lusitaniae (2), C. pelliculosa (1); Brazil: C. intermedia (3), C. haemulonii (2), C. lusitaniae, C. famata, C. norvegiensis (1 each); Colombia: C.
lusitaniae (1); Honduras: C. lusitaniae (3), C. pelliculosa, C. haemulonii, C. albicans+C. glabrata (1 each); Venezuela: C. pelliculosa (1).
doi:10.1371/journal.pone.0059373.t002
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(73.3%) and older children (73.7%). The 30-day survival among
treated patients was 65.3%, and was not different according to the
antifungal agent used as primary treatment.
Table 5 summarizes the antifungal susceptibility tests of the
most frequent Candida bloodstream isolates. For fluconazole,
resistance was observed only in C. krusei (all resistant by definition)
and C. glabrata (7.1%). In addition, SDD was observed in one C.
albicans (0.4%), two C. parapsilosis (1.1%), and 39 (92.9%) C. glabrata
isolates. All isolates were susceptible to voriconazole and
amphotericin B. For anidulafungin, there were two (4.8%) C.
glabrata isolates, one (0.4%) C. albicans and two (1.7%) C. tropicalis
isolates with intermediate susceptibility.
Discussion
In this first multi-country epidemiologic study of candidemia in
Latin America we confirmed some unique epidemiologic features
reported in multicenter studies in Brazil: high incidence, a large
proportion of children (not only neonates), the typical species
distribution with high rates of C. tropicalis and C. parapsilosis and low
rate of C. glabrata candidemia, and low resistance rates. In addition,
we observed some important differences in the epidemiology
across countries.
The proportion of children in this cohort was very high (44.2%).
This is in sharp contrast with series from Europe and the USA. For
example, a 28-month prospective study in six European countries
reported 7.6% of children in a cohort of 2,089 episodes of
candidemia [28]. Other European series reported rates between 2
and 9% [11,12,29,30], and a large prospective study in the USA
reported 9% of children among 1,591 episodes of candidemia
[14]. Another important difference is that while in those series the
majority of children were neonates, in the present series there was
a high proportion of infants (23.6% of the pediatric population).
We observed a high burden of candidemia in the region, with
1.19 cases per 1,000 admissions. The incidence rates were higher
than those reported in the Northern Hemisphere [11,13,15,28,31–
33], but lower compared to Brazilian studies. A multicenter study
reported 2.49 cases per 1,000 admissions [19], but the rates were
even higher in more recent single-center studies (3.6 to 6.0 in one
study [34] and 1.54 to 2.99 in another [35]). However, lower
incidence rates (0.74–0.91 cases per 1,000 admissions) were
observed in private hospitals in this country [36,37]. In the
present study, three hospitals were private and six had both public













Gender, male : female 41:48 54:16 82:56 132:91 87:65 396:276
Age*, median (range) 16 (1–28) 4 (1–11) 5 (1–18) 45 (19–60) 76 (61–98) 26 (0–98)
APACHE II score**, median (range) 15 (6–24) 13.5 (8–24) 18 (4–21) 16 (2–38) 21.5 (10–39) 18 (2–39)
Duration (days) of hospitalization before
candidemia, median (range)
12 (0–28) 19 (0–146) 13 (0–176) 17 (0–162) 20 (0–130) 15 (0–176)
Admission to an ICU 70 (78.7) 34 (48.6) 36 (26.1) 83 (36.8) 78 (51.3) 300 (44.6)
Cancer – 4 (5.7) 46 (33.3) 60 (26.9) 41 (27.0) 151 (22.5)
Hematological malignancy – 1 (1.4) 31 (22.5) 29 (13.0) 8 (5.3) 69 (10.3)
Solid tumor – 3 (4.3) 15 (10.9) 31 (13.9) 33 (21.7) 82 (12.2)
Cardiac disease 18 (20.2) 15 (21.4) 14 (10.1) 34 (15.2) 76 (50.0) 157 (23.4)
Neurological disease 6 (6.7) 11 (5.7) 27 (19.6) 31 (13.9) 43 (28.3) 118 (17.6)
Lung disease 27 (30.3) 19 (27.1) 15 (10.9) 46 (20.6) 60 (39.5) 167 (24.9)
Diabetes mellitus 1 (1.1) – 4 (2.9) 33 (14.8) 38 (25.0) 76 (11.3)
Renal failure 10 (11.2) 10 (14.3) 19 (13.8) 55 (24.7) 56 (36.8) 150 (22.3)
Chronic renal failure – 1 (1.4) 9 (6.5) 24 (10.8) 24 (15.8) 58 (8.6)
Liver disease 2 (2.2) 6 (8.6) 8 (5.8) 34 (15.2) 18 (11.8) 68 (10.1)
Surgery 26 (29.2) 27 (38.6) 58 (42.0) 105 (47.1) 78 (51.3) 294 (43.8)
Abdominal surgery 18 (20.2) 17 (24.3) 29 (21.0) 54 (24.2) 38 (25.0) 156 (23.2)
Mechanical ventilation 60 (67.4) 31 (44.3) 32 (23.2) 102 (45.7) 82 (53.9) 307 (45.7)
Parenteral nutrition 43 (48.3) 18 (25.7) 26 (18.8) 64 (28.7) 41 (27.0) 192 (28.6)
Dialysis 3 (3.4) 3 (4.3) 8 (5.8) 35 (15.7) 27 (17.8) 76 (11.3)
Neutropenia 1 (1.1) 4 (5.7) 30 (21.7) 19 (8.5) 3 (2.0) 57 (8.5)
Central venous catheter 63 (70.8) 38 (54.3) 91 (65.9) 167 (74.9) 124 (81.6) 483 (71.9)
Receipt of antibiotic 85 (95.5) 68 (97.1) 131 (94.9) 211 (94.6) 140 (92.1) 635 (94.5)
Receipt of corticosteroids 12 (13.5) 16 (22.9) 48 (34.8) 87 (39.0) 62 (40.8) 225 (33.5)
Previous use of fluconazole 15 (16.9) 3 (4.3) 22 (15.9) 48 (21.5) 19 (12.5) 107 (15.9)
NOTE: Numbers are no. (%) of patients, unless otherwise indicated. APACHE =Acute Physiologic and Chronic Health Evaluation;
Infants defined as children older than 28 days and younger than 1 year; Elderly defined as patients older than 60 years.
*days for neonates, months for infants and years for the other age strata and overall.
**data available for 258 episodes.
doi:10.1371/journal.pone.0059373.t003
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and private coverage. Therefore, it is possible that these
differences may partly explain the great variety in the incidence
of candidemia observed across countries and across centers within
a country. Although speculative, other factors that may have
contributed to this variation include the characteristics of the
hospitals, with different patient populations and standards of
prophylaxis and empiric therapy.
In our study, species distribution confirmed that in Latin
America, C. albicans, C. parapsilosis and C. tropicalis account for more
than 80% of episodes of candidemia, C. parapsilosis is not clustered
in children, and the frequency of C. glabrata candidemia is lower
than that reported in the Northern Hemisphere [25]. However,
there were some important differences across countries. For
example, Brazil had the highest proportion of candidemia due to
C. glabrata (10%). A trend for an increase in the incidence of C.
glabrata candidemia in Brazilian hospitals has been recently
reported in two studies. In a single-center study, the proportion
of C. glabrata increased from 4.8% in 2008 to 23.5% in 2010. No
association between fluconazole use and the increase in C. glabrata
candidemia was observed [34]. By contrast, another study
observed a higher proportion of candidemia due to C. glabrata in
private hospitals compared to public hospitals. Patients from
private hospitals were more likely to have been exposed to
fluconazole, and C. glabrata isolates from private hospitals were less
susceptible to fluconazole [37]. In the present study, we did not
observe an association between fluconazole exposure and
candidemia due to C. glabrata. On the other hand, C. glabrata
candidemia was more frequent in elderly patients, as reported
elsewhere [38]. Interestingly, Brazilian patients (the country with
the highest proportion of C. glabrata) were significantly older than
patients from other countries (median age 45 years vs. 20 years,
p,0.001). Furthermore, the proportion of isolates with resistance
to fluconazole was low (6.5% only). Taken together, it seems that
there are two epidemiologic scenarios of candidemia due to C.
glabrata: one that is driven by older age, typically with more
fluconazole-susceptible isolates, and other driven by selective
pressure of fluconazole use, with less-susceptible isolates. More
studies are needed to confirm this hypothesis.
Our study confirmed that C. parapsilosis is very prevalent in Latin
America, and is distributed in all age strata, contrasting to studies
from other parts of the globe, in which this species is more
frequent among neonates [39]. We also observed a high
proportion of candidemia episodes caused by C. guilliermondii.
The majority of cases occurred in Honduras, mostly in children. A
pseudo-outbreak of C. guilliermondii candidemia was reported in a
center in Brazil, with most cases occurring in pediatric patients
[40]. The pseudo-outbreak was suspected because of the cluster of
cases in time and place, and also because the large majority of
patients did not have the typical risk factors for candidemia or had
clinical manifestations of infection. In the present study, we
performed a careful review of the clinical characteristics of the
cases, including risk factors, antifungal treatment and outcome,
and did not find any feature suggestive of a pseudo-outbreak.
The antifungal susceptibility tests confirmed previous studies
[25], with very low rates of resistance, except for C. glabrata and C.
krusei and fluconazole. In addition, we observed two C. glabrata
isolates (4.3%) exhibiting higher MICs to anidulafungin. The
clinical relevance of these findings is unknown because although
epidemiologic breakpoints for the echinocandins have been
proposed [26], the correlation between MIC and the outcome is
still uncertain. However, caution should be taken since sporadic
cases of therapeutic failure with echinocandins have been reported
in candidemia due to C. glabrata [41], and data on an animal model














Candida albicans 39 (43.8) 34 (48.6) 41 (29.7) 75 (33.6) 64 (42.1) 253 (37.6)
Candida parapsilosis 24 (27.0) 17 (24.3) 39 (28.3) 67 (30.0) 31 (20.4) 178 (26.5)
Candida tropicalis 13 (14.6) 6 (8.6) 22 (15.9) 49 (22.0) 28 (18.4) 118 (17.6)
Candida guilliermondii 4 (4.5) 11 (15.7) 16 (11.6) 9 (4.0) 4 (2.6) 44 (6.5)
Candida glabrata 3 (3.4) 1 (1.4) 5 (3.6) 10 (4.5) 23 (15.1) 42 (6.3)
Candida krusei 4 (4.5) – 5 (3.6) 9 (4.0) – 18 (2.7)
Received antifungal therapy 71 (79.8) 64 (91.4) 122 (88.4) 191 (85.6) 126 (82.9) 574 (85.4)
Primary treatment*
Fluconazole 25/71 (35.2) 37/64 (57.8) 76/122 (62.3) 141/191 (73.8) 99/126 (78.6) 378/574 (65.8)
d-AMB 39/71 (54.9) 21/64 (32.8) 39/122 (32.0) 27/191 (14.1) 13/126 (10.3) 139/574 (24.2)
Caspofungin 4/71 (5.6) – 3/122 (2.4) 14/191 (7.3) 8/126 (6.3) 29/574 (5.0)
Anidulafungin – 3/64 (4.7) 1/122 (0.8) 3/191 (1.6) 4/126 (3.2) 11/574 (1.9)
Voriconazole 2/71 (2.8) 1/64 (1.6) 1/122 (0.8) 6/191 (3.1) 2/126 (1.6) 12/574 (2.1)
l-AMB 1/71 (1.4) 2/64 (3.1) 2/122 (1.6) – – 5/574 (0.9)
15-day survival** 56 (64.4) 47 (74.6) 95 (76.0) 137 (64.9) 56 (39.4) 391 (62.3)
30-day survival*** 46 (59.7) 44 (73.3) 84 (73.7) 120 (61.9) 52 (37.7) 346 (59.3)
NOTE: Numbers are no. (%) of patients; d-AMB=deoxycholate amphotericin B; l-AMB= lipid formulation of amphotericin B.
Infants defined as children older than 28 days and younger than 1 year; Elderly defined as patients older than 60 years.
*In 12 episodes no information was available regarding antifungal treatment.
**Data available in 628 episodes.
***Data available in 583 episodes.
doi:10.1371/journal.pone.0059373.t004
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suggested that the echinocandins have a fungistatic effect against
this species [42].
In the present study, almost 15% of patients did not receive
treatment. The most likely reason was late diagnosis, since the
majority of such patients died very early after the incident
candidemia. Fluconazole was the leading agent given as primary
treatment. Echinocandins were used infrequently despite their
excellent attributes for the treatment of candidemia, probably
because of its high price compared with deoxycholate amphoter-
icin B and fluconazole. Another interesting observation was that
elderly patients were much less likely to have received deoxycho-
late amphotericin B as primary therapy.
A limitation of our study is that although 21 centers from seven
Latin American countries participated, this may not be represen-
tative of each country, especially those with higher population and
bigger territory, such as Argentina and Brazil. Nevertheless, this is
the first attempt to estimate the burden and to characterize the
epidemiology of candidemia in the region. Additional studies are
needed to expand the epidemiology of candidemia in individual
countries, especially those with no data. In addition, a better
characterization of the epidemiology of candidemia in the
pediatric population is warranted, considering the high burden
and consequences of candidemia in these patients.
In conclusion, this first large epidemiologic study of candidemia
in Latin America showed similar findings as studies conducted in
Brazil: high incidence, high percentage of children, typical species
distribution, with C. albicans, C. parapsilosis and C. tropicalis
accounting for the majority of episodes, and low resistance rates.
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